CBM News and Press, Cambrex Corporation From 05/29/19

EAST RUTHERFORD, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that company management will present at the following ...

Cambrex Corporation (CBM) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Gregory Sargen - Chief Financial Officer and Executive Vice President, Corporate Development and Strategy Steven Klosk - President and Chief Executive Officer Conference Call P...

Cambrex (NYSE: CBM ): Q1 Non-GAAP EPS of $0.60 beats by $0.12 ; GAAP EPS of $0.31. More news on: Cambrex Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference call at 8:30 a.m. ET on May 2, 2019 - EAST RUTHERFORD, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Cambrex Corpo...

EAST RUTHERFORD, N.J., April 30, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that first quarter 2019 financial results will be re...

EAST RUTHERFORD, N.J., April 23, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had opened a new 120m 2 quality control (QC...

EAST RUTHERFORD, N.J., April 10, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 mill...

EAST RUTHERFORD, N.J., March 26, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it will double the liquid packaging capacity and wee...

EAST RUTHERFORD, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m 2 ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...